Clinical Nuclear Medicine · 2018 · 44 citations · 7 references
MedicineNuclear MedicineRadiologyDiagnostic RadiologyGenitourinary OncologyTheranosticsOncologic Nuclear ImagingProstate CancerProstate Cancer ImagingProstate ImagingTumor CharacterizationTumor ImagingProstate Cancer Detection Using Prostate-specific AntigenProstate Cancer TheranosticsProstate-specific Membrane Antigen PetProstate-specific Membrane Antigen Positron Emission TomographyProstate-specific Membrane Antigen RadioligandsProstate-specific Membrane Antigen TheranosticsPsma-pet ImagingTheranostic Agents
PET/CT with Ga-labeled prostate-specific membrane antigen (PSMA) is increasingly recognized as the best imaging modality for disease staging and detection of recurrent prostate cancer. Despite its name, PSMA expression has been reported in a number of nonprostatic benign and malignant pathologies. Apparently, angioneogenesis is the mechanism attributed to increased Ga-PSMA uptake at these sites. Here we illustrate the utility of Ga-PSMA in 5 nonprostatic malignancies that could open up new possibilities for diagnostics and theranostic concepts with PSMA labeled radioligands in nonprostate tumor entities.
7
Diagnostic Value of 68Ga PSMA-11 PET/CT Imaging of Brain Tumors—Preliminary Analysis
Arun Sasikumar, Ajith Joy, M. R. A. Pillai et al. · Clinical Nuclear Medicine · 2016 · 132 citations